Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes)
The DOI matches its Crossref record.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hardiman, O., Al-Chalabi, A., Chio, A., Corr, E. M., Logroscino, G., Robberecht, W., Shaw, P. J., Simmons, Z., & van den Berg, L. H. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.71 · Cited by 1,414
A comprehensive review of amyotrophic lateral sclerosis
Zarei, S., Carr, K., Reiley, L., Diaz, K., Guerra, O., Altamirano, P., Pagani, W., Lodin, D., Orozco, G., & Chinea, A. (2015) · Surgical Neurology International · doi:10.4103/2152-7806.169561 · Cited by 709
Buendia, I., Michalska, P., Navarro, E., Gameiro, I., Egea, J., & León, R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.003 · Cited by 678
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
Mead, R. J., Shan, N., Reiser, H. J., Marshall, F., & Shaw, P. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00612-2 · Cited by 505
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Faissner, S., Plemel, J. R., Gold, R., & Yong, V. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0035-2 · Cited by 459
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
“FDA as a disease-modifying drug for amyotrophic lateral sclerosis that lowers extracellular glutamate levels [29] (Table 1).”
BackgroundBellingham, M. C. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00116.x · Cited by 388
“6) and aspartate release in the spinal dorsal horn [129]; this effect of riluzole on excitatory transmitter release was particularly significant, as it established the in vivo efficacy of riluzole as an inhibitor of glutamate release, as shown in vitro for synaptosomes [77] and brain slices [88].”
BackgroundPharmacological Approaches To Repair the Injured Spinal Cord
Baptiste, D. C., & Fehlings, M. G. (2006) · Journal of Neurotrauma · doi:10.1089/neu.2006.23.318 · Cited by 269
The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder
Wu, K., Hanna, G. L., Rosenberg, D. R., & Arnold, P. D. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.10.007 · Cited by 264
“…through the inhibition of voltagedependent sodium channels (Urbani and Belluzzi, 2000) and the inhibition of P/Q-type calcium channels at the axon terminal, thereby inhibiting synaptic glutamate release (Wang et al., 2004) and stimulating glutamate uptake by astrocytes (Frizzo et.al, 2004).”
Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis
Cheah, B. C., Vucic, S., Krishnan, A., & Kiernan, M. C. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791163939 · Cited by 258
Zarate, C. A., Quiroz, J. A., Singh, J. B., Denicoff, K. D., De Jesus, G., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.023 · Cited by 257
Hawryluk, G. W. J., Rowland, J., Kwon, B. K., & Fehlings, M. G. (2008) · Neurosurgical Focus · doi:10.3171/foc.2008.25.11.e14 · Cited by 252
Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System
Carpanini, S. M., Torvell, M., & Morgan, B. P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00362 · Cited by 207
Miller, O. H., Moran, J. T., & Hall, B. J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.028 · Cited by 200
Riluzole in the Treatment of Mood and Anxiety Disorders
Pittenger, C., Coric, V., Banasr, M., Bloch, M., Krystal, J. H., & Sanacora, G. (2008) · CNS Drugs · doi:10.2165/00023210-200822090-00004 · Cited by 177
Brennan, B. P., Hudson, J. I., Jensen, J. E., McCarthy, J., Roberts, J. L., Prescot, A. P., Cohen, B. M., Pope, H. G., Renshaw, P. F., & Öngür, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.191 · Cited by 168
“The marked increase in the Gln/Glu ratio at day 2 of riluzole treatment was unexpected, given previous in vitro findings that riluzole decreases presynaptic glutamate release (Doble et al, 1992; Martin et al, 1993; Prakriya and Mennerick, 2000; Wang et al, 2004).”
ResultGreen, J. L., dos Santos, W. F., & Fontana, A. C. K. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114786 · Cited by 150
Grant, P., Song, J. Y., & Swedo, S. E. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0009 · Cited by 84
“It also likely reduces glutamate neurotransmitter vesicle fusion with the presynaptic cell membrane, either directly by opening voltage-gated calcium channels (Wang et al. 2004) or indirectly by altering G-protein–mediated signaling (Huang et al. 1997).”
Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Marinova, Z., Chuang, D.-M., & Fineberg, N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170320104237 · Cited by 83
“Riluzole, a drug approved for the treatment of amyotrophic lateral sclerosis, inhibits synaptic glutamate release and stimulates glutamate uptake by astrocytes [66, 67].”
BackgroundTruitt, W. A., Sajdyk, T. J., Dietrich, A. D., Oberlin, B., McDougle, C. J., & Shekhar, A. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0674-y · Cited by 79
Targeting the Modulation of Neural Circuitry for the Treatment of Anxiety Disorders
Farb, D. H., & Ratner, M. H. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009126 · Cited by 55
Sugiyama, A., Saitoh, A., Iwai, T., Takahashi, K., Yamada, M., Sasaki-Hamada, S., Oka, J.-I., Inagaki, M., & Yamada, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.02.012 · Cited by 38
Dulin, J. N., Moore, M. L., & Grill, R. J. (2013) · Journal of Neurotrauma · doi:10.1089/neu.2012.2587 · Cited by 24
Longer-term open-label study of adjunctive riluzole in treatment-resistant depression
Sakurai, H., Dording, C., Yeung, A., Foster, S., Jain, F., Chang, T., Trinh, N.-H., Bernard, R., Boyden, S., Iqbal, S. Z., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.06.065 · Cited by 20
“Riluzole also inhibits voltage-gated calcium channels, leading to reduction of calcium influx and glutamate release (Wang et al., 2004).”
Background
Metadata
- Authors
- Wang, S.-J., Wang, K.-Y., & Wang, W.-C.
- Venue
- Neuroscience
- Publisher
- Elsevier BV
- Published
- 2004-01
- Volume
- 125
- Issue
- 1
- Pages
- 191-201
- ISSN
- 0306-4522 (ISSN-L)
- OpenAlex
- W2027350487
- Cited by
- 210
- References
- 0
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.